In vitro Investigation of Ingavirin® Efficacy Against Influenza B Virus
Abstract
The experimental investigation of Ingavirin® activity against influenza B virus showed that in concentrations 100 and 200 mcg/ml it was efficient in inhibition of the virus reproduction: the cytopathic effect was lowered by 75%, the level of the pathogen accumulation in the MDCK cell culture was decreased by more than 2.0 lg and the formation of the virus specific hemagglutinin was inhibited by more than 90%.
About the Authors
S. YA. Loginova
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
S. V. Borisevich
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
I. A. Semenova
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
G. V. Borisevich
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
V. A. Maksimov
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
V. P. Bondarev
Branch of Central Research Institute No.48, Ministry of Defense of the Russian Federation, Virological Centre, Sergiev Posad
Russian Federation
Russian Federation
V. E. Nebolsin
Valenta Farmacevtica, Moscow
Russian Federation
Russian Federation
References
1. Государственный доклад «О санитарно-эпидемиологической обстановке в Российской Федерации в 2007 году» // www.rospotrebnadzor.ru /documents/doclad/2125.pdf.
2. Государственный доклад «О санитарно-эпидемиологической обстановке в Российской Федерации в 2006 году» // www.rospotreb-nadzor.ru/documents/doclad/1304.zp.
3. Беляев А. Л., Слепушкин А. Н. Современное состояние проблем гриппа и острых респираторных заболеваний (ОРЗ) // http://www.grippol.ru/doc/problma_grippa_i_orvi.doc
4. Influenza in the world. September 2006 — January 2007 // Weekly Epidemiol. Rec. 2007; 82: 10: 77—79.
5. Influenza in the world. September 2006 — August 2007 // Weekly Epidemiol. Rec. 2007; 82: 41: 358—360.
6. Ivanova V. T., Kurochkina Ia. E., Burtseva E. I. et al. The spread and biological properties of epidemic influenza viruses A and B strains circulating in the 2006—2007 season in Russia. Vopr Virusol 2008; 53: 5: 19—23.
7. Meijer A., Meerhoff T. J., Meuwissen L. E. et al. Epidemiological and virological assessment of influenza activity in Europe during the winter 2005—2006. Euro Surveill 2007; 12: 9: 11—12
8. Hatakeyama S., Sugaya N., Ito M. et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007 ; 297 : 13 : 1435—1442.
9. Rena J. Peramivir un nuero y potente inhibidor de la neuraminidasa para el tratamiento de las infecciones pripales. Rev Esp Quimioterap 2006; 19: 4: 317—32.
10. Sugaya N., Mitamura R., Yamazaki M. et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007; 44: 197—202.
11. Логинова С. Я., Борисевич С. В., Максимов В. А., Бондарев В. П. Оценка токсичности неспецифических медицинских противовирусных средств, предназначенных для профилактики и лечения опасных и особо опасных вирусных инфекций. Антибиотики и химиотер 2009; 54: 3—4: 11—14.
12. Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ.М.: Минздрав РФ, 2005.
Review
For citations:
Loginova S.Ya., Borisevich S.V., Semenova I.A., Borisevich G.V., Maksimov V.A., Bondarev V.P., Nebolsin V.E. In vitro Investigation of Ingavirin® Efficacy Against Influenza B Virus. Antibiot Khimioter = Antibiotics and Chemotherapy. 2009;54(7-8):13-15. (In Russ.)
Views:
345
Email this article 